Confo Therapeutics. Lilly is paying $40 million upfront and up to $590 million per programme in back-end payments to Confo in order to get rights to a group of compounds headed by CFTX-1554 ...
Belgium's Confo Therapeutics, another company hoping to tap into the mad rush in the pharma industry for drugs for weight loss, made around €60 million (around $65 million) from its Series B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback